These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 28992757)

  • 1. Newborn cystic fibrosis screening in southeastern Mexico: Birth prevalence and novel CFTR gene variants.
    Ibarra-González I; Campos-Garcia FJ; Herrera-Pérez LDA; Martínez-Cruz P; Moreno-Graciano CM; Contreras-Capetillo SN; León-Burgos V; Maldonado-Solis FA; Alcántara-Ortigoza MA; González Del Angel A; Vela-Amieva M
    J Med Screen; 2018 Sep; 25(3):119-125. PubMed ID: 28992757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.
    Comeau AM; Parad RB; Dorkin HL; Dovey M; Gerstle R; Haver K; Lapey A; O'Sullivan BP; Waltz DA; Zwerdling RG; Eaton RB
    Pediatrics; 2004 Jun; 113(6):1573-81. PubMed ID: 15173476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Negative sweat test in hypertrypsinaemic infants with cystic fibrosis carrying rare CFTR mutations.
    Padoan R; Bassotti A; Seia M; Corbetta C
    Eur J Pediatr; 2002 Apr; 161(4):212-5. PubMed ID: 12014388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improving the Sensitivity and Positive Predictive Value in a Cystic Fibrosis Newborn Screening Program Using a Repeat Immunoreactive Trypsinogen and Genetic Analysis.
    Sontag MK; Lee R; Wright D; Freedenberg D; Sagel SD
    J Pediatr; 2016 Aug; 175():150-158.e1. PubMed ID: 27131402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a Northern European population.
    Sommerburg O; Lindner M; Muckenthaler M; Kohlmueller D; Leible S; Feneberg R; Kulozik AE; Mall MA; Hoffmann GF
    J Inherit Metab Dis; 2010 Oct; 33(Suppl 2):S263-71. PubMed ID: 20714932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Newborn Screening for Cystic Fibrosis in California.
    Kharrazi M; Yang J; Bishop T; Lessing S; Young S; Graham S; Pearl M; Chow H; Ho T; Currier R; Gaffney L; Feuchtbaum L;
    Pediatrics; 2015 Dec; 136(6):1062-72. PubMed ID: 26574590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic dilemmas resulting from the immunoreactive trypsinogen/DNA cystic fibrosis newborn screening algorithm.
    Parad RB; Comeau AM
    J Pediatr; 2005 Sep; 147(3 Suppl):S78-82. PubMed ID: 16202789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Evaluation of 47,213 infants in neonatal screening for cystic fibrosis, using pancreatitis-associated protein and immunoreactive trypsinogen assays].
    Barthellemy S; Maurin N; Roussey M; Férec C; Murolo S; Berthézène P; Iovanna JL; Dagorn JC; Sarles J
    Arch Pediatr; 2001 Mar; 8(3):275-81. PubMed ID: 11270251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis.
    Sarles J; Berthézène P; Le Louarn C; Somma C; Perini JM; Catheline M; Mirallié S; Luzet K; Roussey M; Farriaux JP; Berthelot J; Dagorn JC
    J Pediatr; 2005 Sep; 147(3):302-5. PubMed ID: 16182665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for cystic fibrosis in newborn infants: results of a pilot programme based on a two tier protocol (IRT/DNA/IRT) in the Italian population.
    Corbetta C; Seia M; Bassotti A; Ambrosioni A; Giunta A; Padoan R
    J Med Screen; 2002; 9(2):60-3. PubMed ID: 12133923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neonatal screening strategy for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis.
    Ranieri E; Ryall RG; Morris CP; Nelson PV; Carey WF; Pollard AC; Robertson EF
    BMJ; 1991 May; 302(6787):1237-40. PubMed ID: 2043846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cystic fibrosis newborn screening: the importance of bloodspot sample quality.
    Doull I; Course CW; Hanks RE; Southern KW; Forton JT; Thia LP; Moat SJ
    Arch Dis Child; 2021 Mar; 106(3):253-257. PubMed ID: 32859613
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-tiered immunoreactive trypsinogen-based newborn screening for cystic fibrosis in Colorado: screening efficacy and diagnostic outcomes.
    Sontag MK; Hammond KB; Zielenski J; Wagener JS; Accurso FJ
    J Pediatr; 2005 Sep; 147(3 Suppl):S83-8. PubMed ID: 16202790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Refining the continuum of CFTR-associated disorders in the era of newborn screening.
    Levy H; Nugent M; Schneck K; Stachiw-Hietpas D; Laxova A; Lakser O; Rock M; Dahmer MK; Biller J; Nasr SZ; Baker M; McColley SA; Simpson P; Farrell PM
    Clin Genet; 2016 May; 89(5):539-49. PubMed ID: 26671754
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Status of Genetic Diagnosis Laboratories and Frequency of Genetic Variants Associated with Cystic Fibrosis through a Newborn-Screening Program in Turkey.
    Bozdogan ST; Mujde C; Boga I; Sonmezler O; Hanta A; Rencuzogullari C; Ozcan D; Altintas DU; Bisgin A
    Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33572515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A survey of newborn screening for cystic fibrosis in Europe.
    Southern KW; Munck A; Pollitt R; Travert G; Zanolla L; Dankert-Roelse J; Castellani C;
    J Cyst Fibros; 2007 Jan; 6(1):57-65. PubMed ID: 16870510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondhand Smoke Exposure and Serum Trypsinogen in Cystic Fibrosis Carriers.
    Ellery KM; Kopp B; Conwell DL; Gariepy C
    Pancreas; 2019 Oct; 48(9):1155-1159. PubMed ID: 31593019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newborn screening for cystic fibrosis in Wisconsin: nine-year experience with routine trypsinogen/DNA testing.
    Rock MJ; Hoffman G; Laessig RH; Kopish GJ; Litsheim TJ; Farrell PM
    J Pediatr; 2005 Sep; 147(3 Suppl):S73-7. PubMed ID: 16202788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neonatal screening for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis: four years' experience.
    Ranieri E; Lewis BD; Gerace RL; Ryall RG; Morris CP; Nelson PV; Carey WF; Robertson EF
    BMJ; 1994 Jun; 308(6942):1469-72. PubMed ID: 8019280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cystic fibrosis newborn screening in Denmark: Experience from the first 2 years.
    Skov M; Baekvad-Hansen M; Hougaard DM; Skogstrand K; Lund AM; Pressler T; Olesen HV; Duno M
    Pediatr Pulmonol; 2020 Feb; 55(2):549-555. PubMed ID: 31682332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.